Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
CAMBRIDGE, Mass., Oct. 25, 2017 -- 2X Oncology, Inc. ("2X" or the "Company"), a precision medicine company developing targeted therapeutics to address significant unmet needs in hard-to-treat cancers, announced today that the Company will participate in the Life Sciences Summit 2017 on November 1-2 in New York City and the Jefferies 2017 London Healthcare Conference on November 15-16.
Chief Executive Officer George O. Elston will participate in and hold 1x1s with investors at both conferences, joined by Chief Financial Officer Jarne Elleholm.
Additionally, Mr. Elston will present in the Emerging Company Showcase at the Life Sciences Summit on Thursday, November 2, 2017 at 3:30pm EDT, with a discussion period to follow.
Investors wishing to meet with 2X Oncology at or around either conference should notify the respective conference one-on-one desk, or contact Amy Raskopf to schedule a meeting.
About 2X Oncology
2X Oncology Inc. is a clinical stage precision medicine company developing targeted therapeutics addressing significant unmet needs in hard-to-treat cancers. Our pipeline leverages a proprietary Drug Response Predictor (DRP®) technology generating drug specific companion diagnostics to identify patients who are most likely to respond and benefit from treatment. DRP® also identifies likely non-responder patients, providing a precision medicine approach for the treatment of patients who can benefit from our therapies.
The 2X pipeline of product candidates, including a PARPi, are focused on the treatment of breast, ovarian, prostate and pancreatic cancers and primary and secondary brain tumors. These programs have demonstrated clinical efficacy and safety and are positioned to enter focused Phase 2 studies with study data and potential accelerated approval filings expected in 2H 2018.
A Cambridge, MA based spin-out from Oncology Venture ApS, 2X works in close collaboration with Oncology Venture and leverages a Danish registry of over 1,200 cancer patients for initial clinical studies. Learn more at 2xoncology.com.
DRP® is a registered trademark of Medical Prognosis Institute A/S.
Contact Amy Raskopf +1 917.673.5775 [email protected] www.2xoncology.com Twitter: @2xoncology
